Rigel Pharmaceuticals Stock Price Prediction
| RIGL Stock | USD 0.97 0.01 1.02% |
Oversold Vs Overbought
33
Oversold | Overbought |
Quarterly Earnings Growth (0.48) | EPS Estimate Next Quarter (0.02) | EPS Estimate Current Year (0.09) | EPS Estimate Next Year 0.06 | Wall Street Target Price 4.53 |
Using Rigel Pharmaceuticals hype-based prediction, you can estimate the value of Rigel Pharmaceuticals from the perspective of Rigel Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Rigel Pharmaceuticals using Rigel Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Rigel using crowd psychology based on the activity and movement of Rigel Pharmaceuticals' stock price.
Rigel Pharmaceuticals Implied Volatility | 0.0 |
Rigel Pharmaceuticals' implied volatility exposes the market's sentiment of Rigel Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Rigel Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Rigel Pharmaceuticals stock will not fluctuate a lot when Rigel Pharmaceuticals' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Rigel Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Rigel because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Rigel Pharmaceuticals after-hype prediction price | USD 0.89 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Rigel |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rigel Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rigel Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Rigel Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Rigel Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Rigel Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Rigel Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Rigel Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Rigel Pharmaceuticals' historical news coverage. Rigel Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.04 and 4.54, respectively. We have considered Rigel Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Rigel Pharmaceuticals is very risky at this time. Analysis and calculation of next after-hype price of Rigel Pharmaceuticals is based on 3 months time horizon.
Rigel Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Rigel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rigel Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Rigel Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.66 | 3.65 | 0.08 | 0.04 | 8 Events / Month | 1 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.97 | 0.89 | 8.25 |
|
Rigel Pharmaceuticals Hype Timeline
Rigel Pharmaceuticals is at this time traded for 0.97. The entity has historical hype elasticity of -0.08, and average elasticity to hype of competition of -0.04. Rigel is forecasted to decline in value after the next headline, with the price expected to drop to 0.89. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -8.25%, whereas the daily expected return is at this time at -0.66%. The volatility of related hype on Rigel Pharmaceuticals is about 6246.43%, with the expected price after the next announcement by competition of 0.93. About 64.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.11. Rigel Pharmaceuticals had not issued any dividends in recent years. The entity had 1:9 split on the 25th of June 2003. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Rigel Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Rigel Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Rigel Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Rigel Pharmaceuticals' future price movements. Getting to know how Rigel Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Rigel Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ARTLW | Artelo Biosciences | (0.01) | 3 per month | 25.04 | 0.12 | 73.87 | (50.64) | 398.54 | |
| NTRB | Nutriband | (0.11) | 6 per month | 4.25 | 0.20 | 11.60 | (6.72) | 44.56 | |
| SABS | SAB Biotherapeutics | (0.06) | 7 per month | 0.00 | (0.13) | 6.01 | (8.86) | 30.36 |
Rigel Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Rigel price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Rigel using various technical indicators. When you analyze Rigel charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Rigel Pharmaceuticals Predictive Indicators
The successful prediction of Rigel Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Rigel Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Rigel Pharmaceuticals based on analysis of Rigel Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Rigel Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Rigel Pharmaceuticals's related companies. | 2021 | 2022 | 2024 (projected) | Graham Number | 0.65 | 0.8 | 0.69 | Receivables Turnover | 9.65 | 2.98 | 3.63 |
Story Coverage note for Rigel Pharmaceuticals
The number of cover stories for Rigel Pharmaceuticals depends on current market conditions and Rigel Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Rigel Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Rigel Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Rigel Pharmaceuticals Short Properties
Rigel Pharmaceuticals' future price predictability will typically decrease when Rigel Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Rigel Pharmaceuticals often depends not only on the future outlook of the potential Rigel Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rigel Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 174 M | |
| Cash And Short Term Investments | 56.9 M |
Additional Information and Resources on Investing in Rigel Stock
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:Check out Rigel Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share (0.11) | Revenue Per Share 0.684 | Quarterly Revenue Growth 0.133 | Return On Assets (0.08) |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.